m+Medelevator.RU
← Поиск публикаций
Molecular therapy : the journal of the American Society of Gene Therapy · 2026

A singular base-editing platform for polyfunctional multiplex engineering of immune cells.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Skeate Joseph G, Slipek Nicholas J, Lahr Walker S, Roy Shambojit, Wick Bryce J, Kar Bibekananda, Chang Jae-Woong, Stelljes Erin M, Gilkey Alexandria K, Thenge Prateek P, Diers Miechaleen D, Krueger Joshua B, Niemeyer Ethan M, Lonetree Cara-Lin, Kluesner Mitchell G, Bell Jason B, Clement Kendell, Provenzano Paolo P, Moriarity Branden S, Webber Beau R

Аннотация

Current methods to engineer antigen-specific receptors rely on randomly integrating vectors or double-strand-break-induced targeted integration, both of which pose safety risks. To implement an all-in-one tool for multiplex knockout (KO) and knockin (KI), we expand the use of base editor nickase activity to stimulate homology-directed repair (HDR) and insert clinically relevant chimeric antigen receptors (CARs) into specific loci. Through a novel single-guide RNA design strategy and a DNA template delivered by a recombinant adeno-associated virus, we enhanced the efficiency of ABE8e-stimulated HDR in human T cells. By combining KI of CD19, CD33, or mesothelin-targeting CARs with >95% quadplex gene KO (B2M/CD3E/PDCD1/CISH), we achieve single-step generation of highly functional off-the-shelf CAR T cell products with enhanced function. Importantly, we found no detectable translocations or significant off-target edits and demonstrated efficacy against multiple cancer lines and a suppressive 3D spheroid culture model. This efficient engineering process of "Iterative Nicking for Synchronous Engineered Reprogramming of T cells" (INSERT) establishes a safe, simplified platform for advanced therapeutic CAR T engineering.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты